Work

Evaluating liver type fatty acid binding protein as a diagnostic and prognostic biomarker in metabolic dysfunction-associated steatotic liver disease in pediatric patients

Year: 2025

Type: article

Abstract: BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD), is a common liver disorder, predicted to increase globally. Currently, non-invasive methods are proposed for the assessment of (MASLD). This study aimed to investigate the use of serum Liver Type Fatty Acid Binding Protein (L-FABP) concentration as a diagnostic and prognostic biomarker in pediatric MASLD patients and to evaluate its relationship with steatosis and fibrosis. METHODS: An observational, cross-sectional study on paediatric MASLD patients. Serum levels of L-FABP and hepatic biochemical markers were measured and analyzed. Statistical analyses evaluated the association between L-FABP and other markers, while logistic regression and ROC curves assessed its diagnostic accuracy. RESULTS: Serum L-FABP levels showed a significant difference between the MASLD and control groups (P < 0.0001). The results of logistic regression revealed that each one-unit elevation of L-FABP level was associated with 144.5% higher odds of being MASLD (95% CI: 129.3% - 167.8%). A receiver operating characteristics (ROC) curve was constructed to assess the diagnostic accuracy of L-FABP. The resulted area under the ROC curve (AUC) was 0.885. The cutoff value was 5.7 ng/ mL, with sensitivity of 72.73%, and a specificity of 93.62%. The results also showed that the odds ratio of progressing from stage F2 to F3 increases by 108.9% (95% CI: 87.2% - 141.4%) for each one-unit increase in serum L-FABP level. CONCLUSION: L-FABP shows promise as a non-invasive biomarker for diagnosing and monitoring MASLD in pediatric patients. Its association with disease stages suggests its utility in assessing disease progression, particularly in advanced stages.

Source: PLoS ONE

DOI: 10.1371/journal.pone.0333581